Nomilin has been shown to inhibit the proliferation of estrogen receptor-negative (ER-) and -positive (ER+) human breast cancer cells in culture [60], and the anti-proliferative activity of nomilin is mediated via caspase-7 dependent pathways in breast cancer cells [13]. The gene discussed is ESR1; the disease is breast carcinoma.